<DOC>
	<DOCNO>NCT01707329</DOCNO>
	<brief_summary>This phase II randomise , double blind , placebo control , multicentre trial design assess efficacy safety continuous icotinib plus chemotherapy versus chemotherapy alone patient progress benefit previous second third-line icotinib treatment ( 6 month ) locally advanced metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>Icotinib Combination With Chemotherapy Versus Chemotherapy Alone Patients Progressed After Icotinib Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm stage IIIB/IV lung cancer ( exclude patient confirm sputum cytology ) No previous target treatment gefitinib , erlotinib . With measurable disease ( long diameter &gt; =10mm Spiral compute tomography ( CT ) &gt; =20mm conventional CT ) accord RECIST Criteria WHO performance status ( PS ) &lt; = 2 N &gt; =1.5×109/L , Plt &gt; =1.0×109/L , Hb &gt; =10g/dL ; AST &amp; ALT &lt; 3ULN ( without liver metastasis ) &lt; 5ULN ( liver metastasis ) .TBIL &lt; =1.5ULN . Signed date informed consent start specific protocol procedure . Allergic icotinib Patients metastatic brain tumor symptom . Experience AntiEGFR ( epidermal growth factor receptor ) Monoclonal Antibody small molecular compound therapy gefitinib , erlotinib Cetuximab . Severe systemic disease control unstable uncompensated respiratory , cardiac , liver , renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>